Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewProtecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsAtazanavir pharmacokinetics with and without tenofovir during pregnancyEfficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Effect of pregnancy on emtricitabine pharmacokinetics.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Individualization of antiretroviral therapy.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.Reduced indinavir exposure during pregnancy.A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancyPharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Basic obstetric pharmacology.Adverse drug reactions associated with antiretroviral therapy during pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Antiretroviral Pharmacokinetics in Pregnant Women.Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline.The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q28109657-877724AA-2A08-4F4F-9202-6BF84DA7FDC7Q34429204-7F352FF1-FEEB-4E05-959E-1B9B0486D3B9Q34483505-EC9F8224-BBD0-4C15-B82A-498CDA249CEAQ34710705-4A71C0C8-37E9-4373-9DE3-F145BFEC80ECQ34730950-EAFB7A26-7A48-44B2-A7F1-3EBD07F42F66Q35074548-81D220B8-53E1-4B8E-9B05-985C30965198Q35597592-24B487A1-A361-4F26-A3B4-4B255687331DQ35627832-203CF5CC-7574-43DF-A0CA-9136F37F0A9BQ35689226-CE246852-E875-42F3-9A68-B132DE578972Q35930696-3CFC45F1-2D5C-471E-8242-94E43B0F8A73Q35960706-317E7533-8762-4B37-9092-C7C70F3B890BQ36084313-0B86079C-04BD-4903-BF67-887786615698Q36439051-67465198-42B8-40F5-88C7-A5CB90926A56Q36441423-4F784019-7C19-44A5-833D-5F826D3CDE9CQ36727919-F2140F70-17A1-4F39-A7E8-E55979B8A803Q36763160-6AA3BCCA-746C-474F-B277-56FDA205B685Q36930395-C59A73A7-408C-4759-A156-BF67FE4585F7Q37161917-8F1880A6-CA3D-47AF-B9F2-479E2F241B3FQ37286950-D7FC915F-9981-407F-A0DD-A177E808A8B2Q37600844-9DBDCC6B-F7CC-45A1-8844-E597FA3818FDQ37712960-874A87D3-0A45-421C-9ADF-A4733D85D7FCQ38047214-BAF0DD15-CC2D-49F1-88C0-143A54A89AF2Q38051400-0FA6CFB1-C3F8-4C0B-A922-93277B09CA56Q38081072-781396A7-C8DD-4A35-9B3F-81DED2C8C2F0Q38256590-2156E82C-1473-49C8-B3A7-3A1D4B1102A8Q38267557-8ED8BE66-B47F-4B8C-A245-B37F36B8BEFBQ38325427-6C933C93-9BEF-4A7C-9F44-598852A723E8Q38571596-C8CB45F7-C5E2-4E65-8D56-7E90BFCEA921Q40046821-EB63A936-6795-4B17-8A62-856C5CE7A790Q40046869-70ADB445-21B7-4504-B8F5-A1F84154274AQ41066112-274406FE-F439-4F1D-AA66-6700CF018098Q41665599-B0F640E9-B95C-407A-A60F-CB55D49C4DADQ41681837-D4C11CE1-5E44-408C-8A52-8100BD001DAEQ47548999-F819AC30-9EE4-4E2B-B641-297B759D7F6DQ51366677-201DA880-72C9-448D-B20B-B4B2D995308CQ57076282-294367E0-AC4A-4889-96E0-7DECC2A296AA
P2860
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@ast
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@en
type
label
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@ast
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@en
prefLabel
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@ast
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@en
P2093
P2860
P1476
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
@en
P2093
Alice M Stek
Brookie M Best
Chengcheng Hu
Edmund V Capparelli
International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team
Jennifer S Read
Mark Mirochnick
Sandra K Burchett
Steven S Rossi
P2860
P304
P356
10.1097/QAI.0B013E3181D6C9ED
P407
P577
2010-08-01T00:00:00Z